NeurAxis's robust sales growth and disciplined cost management have set the stage for achieving cash flow breakeven in 2026. Notably, recent investments from life science-focused funds have bolstered ...

NeurAxis, Inc. has announced its achievements from 2024 and outlined its vision for 2025 in a letter from CEO Brian Carrico. The company, focusing on neuromodulation therapies for chronic ...

Revenues in 4Q24 increased approximately 50% versus 4Q23Cash balance as of 12/31/24 was approximately $3.7 million CARMEL, Ind., Jan. 08, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis ...

NeurAxis, Inc. (NASDAQ:NRXS – Get Free Report) fell 4.1% during trading on Tuesday . The stock traded as low as $2.50 and last traded at $2.59. 40,873 shares were traded during trading, an increase of ...

NeurAxis reported a 50% revenue increase in Q4 2024, reaching approximately $800,000, with a cash balance of $3.7 million. NeurAxis, Inc. reported a significant revenue increase of approximately ...

CARMEL, Ind., Jan. 06, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...

NeurAxis (NRXS) announced that CEO Brian Carrico has published a letter to shareholders. “We are thrilled to connect with you as we celebrate ...

CARMEL, Ind., Jan. 13, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company ...

CARMEL, Ind., Jan. 13, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company ...

We are thrilled to connect with you as we celebrate NeurAxis's remarkable achievements in 2024 and anticipate the exciting opportunities ahead. This is a pivotal time for our company as we strive ...

CARMEL, Ind., Jan. 13, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a ...